Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
115 hedge funds and large institutions have $215M invested in Enzo Biochem, Inc. in 2017 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 49 reducing their positions, and 13 closing their positions.
190% more call options, than puts
Call options by funds: $700K | Put options by funds: $241K
1% less funds holding
Funds holding: 116 → 115 (-1)
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
31% less capital invested
Capital invested by funds: $313M → $215M (-$97.9M)
37% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 49
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$4.87M |
| 2 |
Renaissance Technologies
New York
|
+$1.89M |
| 3 |
Millennium Management
New York
|
+$1.57M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.27M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$1.24M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EGA
Evermore Global Advisors
Summit,
New Jersey
|
-$38.6M |
| 2 |
EI
EAM Investors
Solana Beach,
California
|
-$2.24M |
| 3 |
MCM
McKinley Capital Management
Anchorage,
Alaska
|
-$1.97M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$974K |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$947K |
ENZ Hedge Fund Activity: Q4 2017 in Review
115 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q4 2017, worth a combined $215M — down 31% from $313M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of ENZ and 12 opened new positions — a net loss of 1 holder — while 49 trimmed existing stakes and 31 added.
The largest buyer was Wellington Management Group, adding an estimated $4.87M. The largest seller was Evermore Global Advisors, exiting entirely with an estimated $38.6M sold.
- 115 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q4 2017, down from 116 in Q3 2017.
- Funds reported $215M of Enzo Biochem, Inc. stock for Q4 2017, down 31% quarter-over-quarter.
- 12 funds opened new Enzo Biochem, Inc. positions in Q4 2017 and 13 closed out, a net change of -1 holder.
- The largest Enzo Biochem, Inc. buyer in Q4 2017 was Wellington Management Group, an estimated $4.87M added.
- The largest Enzo Biochem, Inc. seller in Q4 2017 was Evermore Global Advisors, an estimated $38.6M sold.
Based on aggregated 13F filings for Q4 2017.